Pharmaceuticals

Tardive Dyskinesia Therapeutics Market Outlook 2026–2030: Key Business Drivers and Trends

February 18, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the tardive dyskinesia therapeutics market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Tardive Dyskinesia Therapeutics Market expected to reach by 2030?

The tardive dyskinesia therapeutics market size has experienced strong growth in recent years. It is forecast to expand from $3.12 billion in 2025 to $3.35 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. Several factors contributed to this growth during the historic period, including limited treatment options for tardive dyskinesia, a dependence on conventional antipsychotic management, low patient awareness, the increasing prevalence of antipsychotic use, and restricted access to specialty treatment centers.

The tardive dyskinesia therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $4.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. Factors driving this growth during the forecast period include the introduction of innovative treatments for tardive dyskinesia, higher research and development spending on neurological conditions, a growing inclination towards homecare environments, the establishment of more specialty treatment centers, improved patient surveillance, and the rise of digital therapeutic solutions. Key trends expected during this period involve the increasing uptake of deutetrabenazine and valbenazine, a stronger emphasis on individualized neurological treatments, the broadening of homecare and remote treatment avenues, heightened public understanding of drug-induced tardive dyskinesia, and a focus on ensuring safety and adherence in prolonged treatment regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp

What Drivers Are Driving Adoption Within The Tardive Dyskinesia Therapeutics Market?

The escalating prevalence of mental health disorders is expected to drive the growth of the tardive dyskinesia therapeutics market moving forward. Mental health disorders are conditions that affect an individual’s thoughts, emotions, behavior, or functioning, often resulting in significant distress or challenges in daily life. The increase in these disorders stems from growing social isolation, as the shift toward digital communication and rapid lifestyles has diminished meaningful in-person interactions, leading to greater feelings of loneliness and emotional strain. Tardive dyskinesia therapeutics support mental disorder patients by managing involuntary movement symptoms caused by prolonged antipsychotic use, thereby enhancing treatment adherence and overall quality of life. For instance, in 2024, according to the National Alliance On Mental Illness, a US-based organization, among people in the U.S. aged 18-44, psychosis spectrum and mood disorders are responsible for nearly 600,000 hospitalizations each year. Therefore, the rising prevalence of mental health disorders propels the tardive dyskinesia therapeutics market.

What Segments Are Included Within The Tardive Dyskinesia Therapeutics Market?

The tardive dyskinesia therapeutics market covered in this report is segmented –

1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs

2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form

3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia

4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings

Subsegments:

1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel

2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel

3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration

Which Trends Are Influencing The Development Of The Tardive Dyskinesia Therapeutics Market?

Leading companies in the tardive dyskinesia therapeutics market are concentrating on developing advanced products, such as once-daily treatment options, to help maintain more consistent drug levels in the body. Once-daily treatment options refer to medications or therapies designed for once-a-day intake, simplifying dosing schedules and improving patient adherence. For instance, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved AUSTEDO XR tablets for treating adults with tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. The recent approval of AUSTEDO XR offers patients proven effectiveness in managing involuntary movements, along with the added convenience of a once-daily, single-pill dosage. This new formulation delivers clinically therapeutic doses confirmed by pivotal clinical trials. Additionally, it is now available in four different tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

Who Are The Major Companies Operating In The Tardive Dyskinesia Therapeutics Market?

Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Tardive Dyskinesia Therapeutics Market?

North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tardive Dyskinesia Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24718&type=smp

Browse Through More Reports Similar to the Global Tardive Dyskinesia Therapeutics Market 2026, By The Business Research Company

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Bipolar Disorder Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795